Skip to main content


22-11-2022 | Dulaglutide | News

FDA clears dulaglutide for adolescents

Click through to read more on this announcement

01-11-2022 | Medications | News

Triple agonist shows early promise for type 2 diabetes

A novel triple receptor agonist has demonstrated an acceptable safety profile and promising reductions in blood glucose and bodyweight in a phase 1b trial reported in The Lancet.

04-06-2022 | ADA 2022 | Conference coverage | News

AWARD-PEDS: Dulaglutide improves glycemic control for youths with type 2 diabetes

Dulaglutide delivers significant reductions in glucose levels for youths with type 2 diabetes, report the AWARD-PEDS investigators.

Patient with erectile dysfunction (symbolic image with models)

23-06-2021 | Complications | News

Dulaglutide may reduce some erectile dysfunction in type 2 diabetes

Long-term dulaglutide use may reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes, particularly those with underlying cardiovascular disease, shows an exploratory analysis of REWIND data.

13-01-2021 | Dulaglutide | News

Dulaglutide reduces total CVD burden in REWIND population

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

Injection pen

11-01-2021 | Dulaglutide | News

AWARD 11 supports higher dulaglutide doses

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

21-12-2020 | Dulaglutide | News

Longer treatment persistence with dulaglutide vs other GLP-1 receptor agonists in type 2 diabetes

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

18-09-2020 | Dulaglutide | News

Add-on dulaglutide may reduce liver fat in people with type 2 diabetes, NAFLD

Results from the D-LIFT trial suggest a reduction in liver fat content when dulaglutide, a glucagon-like peptide-1 receptor agonist, is added to standard care treatment in people with concurrent type 2 diabetes and non-alcoholic fatty liver disease.